QVance AB Announces Collaboration with SKAN
QVance AB, Huddinge, Sweden has today announced it has entered into a collaboration with SKAN AG securing a rigorous sterile environment for the performance of quality control analytics for cell and gene therapy product development and release at QVance’s site in Huddinge.
SKAN is recognised as a global leader for provision of high-class isolators, cleanroom devices and decontamination processes for aseptic handling of biopharmaceutical substances, such as advanced therapy medicinal products (ATMPs). Through this collaboration SKAN has installed a pure2 isolator in QVance’s cleanroom, providing a sterile, Good Manufacturing Practice (GMP) compliant environment for the handling of samples, allowing microbiological testing for drug substance and product release.
This is the first isolator that has been delivered and installed by SKAN and its distributor, Milmedtek, in Sweden.
“QVance is proud to be SKAN’s first customer for the pure2 isolator in Sweden. As a quality control company, it is important to us that the equipment we have in place is of a rigorously high quality to ensure the best service to our customers,” says QVance’s CEO Lindsay Davies. “SKAN’s branding and reputation proceeds itself, and this collaboration is of significant importance to QVance as we built our own company name in quality service provision of the highest standards for safety testing.”
"We at the SKAN AG Pure Solutions International department, are proud to be a contributing partner of QVance's providing the pure2 isolator for their new quality control facilities. Supporting QVance's mission in providing the best service to their customers. For SKAN this partnership shows again the importance of the development of ATMP's and the suitability of the pure2 isolator for this market segment. We thank QVance for choosing Skan's pure2 isolator and their trust in us and the product. We look forward to a long lasting and fruitful partnership with QVance." says Davide Profeta, Head of the Pure Solutions International Department of SKAN AG.
For more information, please contact:
Lindsay Davies
QVance AB
Email: info@qvance.se
Website: www.qvance.se
LinkedIn https://www.linkedin.com/company/qvance/
QVance AB is the daughter company of NextCell Pharma AB
For more information regarding NextCell Pharma please contact:
Mathias Svahn, CEO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com
Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma
About QVance AB
QVance is a quality analytics service provider for advanced therapies. The company’s vision is to be a one-stop analytics service supporting customers throughout development and drug product lifecycle.